Minoxidil

Combining PRP with pharmacological support during FUE hair transplantation significantly improves follicle survival, growth rates, and hair strength compared to pharmacological support alone.

PRP alone and in combination with minoxidil significantly improved hair count, density, terminal hair count, and increased the anagen ratio; the combination also significantly reduced vellus hair count and density.

Combining minoxidil with low-level laser therapy did not produce a statistically significant improvement in hair count or hair diameter compared to minoxidil alone in patients with androgenic alopecia.

Established therapies such as oral finasteride, topical minoxidil, and hair transplantation can reduce hair loss and promote regrowth in many patients, although response varies and novel approaches are needed.

Combination LLLT and minoxidil produced significantly greater increases in hair density and hair shaft diameter, and higher patient satisfaction, compared to minoxidil monotherapy.

Combining topical finasteride 0.1% with minoxidil 5% did not yield additional improvement in hair density, diameter, or terminal hair rate compared to minoxidil 5% alone after 12 weeks, although both regimens produced significant increases from baseline.

Topical minoxidil promotes hair regrowth in androgenetic alopecia and other hair loss conditions but requires daily application; low-dose oral minoxidil shows off-label efficacy for various hair loss disorders while aiming to avoid systemic side effects.

Dutasteride shows greater efficacy than finasteride for treating androgenetic alopecia, while maintaining a comparable safety profile.

A consensus of experts identified seven recommended interventions for AGA, including oral and topical finasteride, dutasteride, and minoxidil, while identifying 17 interventions that are not recommended.

The review highlights that while FDA-approved treatments are limited, natural supplements like saw palmetto and pumpkin seed oil show promise in inhibiting 5-alpha-reductase and promoting hair density.

The review discusses the potential of topical dutasteride and nanocarrier delivery systems to provide an effective alternative to oral treatments while minimizing systemic absorption.

The review summarizes that finasteride and minoxidil are the primary approved treatments, while noting ongoing development of drugs targeting inflammation, fibrosis, and energy metabolism.

Scalp cooling is the current standard for preventing chemotherapy-induced alopecia; minoxidil, photobiomodulation, and PRP are used to promote hair regrowth, though supporting evidence varies.

Low-dose oral minoxidil produced clinical improvement in about 63% of AGA patients after 6 months, with higher response rates in men (73%) and in patients with low hair follicle sulfotransferase activity (85%).

Both 5% topical minoxidil and 1 mg/day oral minoxidil produced significant within-group improvements in hair shaft diameter after 6 months, but there were no significant differences between the groups; photographic density improved significantly in the topical group at multiple scalp distances, yet between-group differences were not significant, and patient satisfaction exceeded 60% in both arms.

Emerging therapies such as low-level laser therapy, microneedling, platelet-rich plasma, and stem cell therapy show promise for promoting hair regrowth, while conventional treatments like minoxidil and finasteride remain effective but have limitations.

Topical and low-dose oral minoxidil showed promise for stabilizing disease and promoting hair regrowth in various scarring alopecia subtypes, with generally good tolerability.

The study investigates the comparative efficacy of topical minoxidil, oral biotin, and their combination on hair growth in men, but specific numeric results are not provided in the abstract.

A combined rosemary and neem extract (2:1) demonstrated superior antifungal activity against dandruff-causing agents compared to ketoconazole and outperformed minoxidil in hair growth trials.

Several natural ingredients including saw palmetto, pumpkin seed oil, melatonin, caffeine, and rosemary oil showed effectiveness in treating AGA compared to baseline or minoxidil.

The review summarizes the potential of various herbal compounds, specifically highlighting rosemary oil as a promising natural alternative for managing androgenetic alopecia.

Combination therapy of topical minoxidil and microneedling significantly increases total hair count compared to minoxidil alone, though it did not show a statistically significant increase in hair diameter.

Various over-the-counter, prescription, and procedural treatments successfully promote hair growth, suggesting that a multifaceted, individualized approach is most effective.

Low-dose oral minoxidil has demonstrated a favorable efficacy and safety profile for both male and female androgenetic alopecia.

The paper outlines standard treatments for different alopecia types, noting minoxidil as first-line for androgenetic alopecia and various therapies for focal hair loss.

Laser and light therapy combined with topical minoxidil significantly reduces alopecia severity scores and improves treatment response compared to minoxidil alone, with lower recurrence at 1 year and similar adverse event rates.

Topical and oral minoxidil and topical finasteride may be useful for pediatric androgenetic alopecia, and hair transplantation can be considered for selected female cases.

Over a year of treatment, about half of patients experienced hair improvement and another 42.9% had stabilization, showing a significant benefit over untreated controls.

Various treatments including 5-alpha reductase inhibitors, oral minoxidil, and PRP show efficacy, though evidence for some newer or non-pharmacological methods remains limited.

Standard treatments like topical minoxidil and oral finasteride are established, while newer modalities like PRP, LLLT, and oral minoxidil show encouraging results but lack standardized protocols.

Chemotherapy-induced alopecia affects approximately 65% of patients; current FDA-cleared prevention is limited to scalp cooling, while regrowth options include minoxidil, PBMT, and PRP.

Topical minoxidil remains the first-choice treatment with high evidence, though approximately 40% of patients do not respond to it.

The review provides an update on FDA-approved treatments (minoxidil and finasteride) as well as various non-FDA-approved, emerging, and alternative therapies for AGA.

In mice with chemotherapy-induced alopecia, hyaluronic acid microneedle delivery of minoxidil at one-tenth the standard topical dose produced greater hair growth than conventional topical minoxidil treatment.

PRP therapy, especially when combined with minoxidil or finasteride, tends to increase hair density and count, but the magnitude of benefit varies widely due to heterogeneous preparation and treatment protocols.

The review discusses various promising topical, oral, and energy-based therapies, noting growing evidence for their efficacy in treating hair loss.

Natural products such as saw palmetto, caffeine, and rosemary oil may serve as alternatives or adjuncts to conventional minoxidil and finasteride treatments for male AGA.

The review outlines various current and emerging therapies for hair loss, including pharmacological agents, devices, and cellular therapies.

Microneedling serves as an effective adjunct therapy for androgenic alopecia when paired with minoxidil, growth factors, or PRP, and shows promise as a standalone therapy for alopecia areata.

Traditional treatments like corticosteroids and minoxidil have limited efficacy and high recurrence rates, while new strategies like JAK inhibitors and biologics are emerging.

Topical minoxidil is effective for AGA in both sexes, with 2% showing peak growth at one year. Oral minoxidil (5 mg/day) is significantly more effective than topical formulations in males after 6 months.

Topical finasteride (0.25% spray or 1% gel) demonstrates efficacy similar to 1 mg oral finasteride in increasing hair density and inhibiting plasma DHT.

Dutasteride 0.5 mg/d is ranked as the most effective treatment, followed by higher doses of finasteride and minoxidil.

Across 12 included trials, PRP showed a positive treatment effect in 84% of studies, with 50% demonstrating statistically significant improvement on objective measures, and consistent gains in hair density and thickness; it was reported as a safe and effective alternative to minoxidil and finasteride with few adverse effects.

Finasteride may promote hair regrowth in women with FPHL, but its use is limited by potential teratogenic risks; topical finasteride and dutasteride are explored as alternative strategies.

Topical finasteride, ketoconazole, and C17P show promise for male pattern hair loss, with topical finasteride particularly effective when combined with minoxidil. C17P shows potential for acne vulgaris.

Microneedling monotherapy is more effective than 5% topical minoxidil alone, and combining microneedling with 5% minoxidil provides a significant additional increase in total hair count compared to microneedling monotherapy.

The review outlines various FDA-approved and non-FDA-approved therapies for AGA, emphasizing that treatment selection must balance efficacy, side effects, compliance, and cost.

Oral minoxidil at low doses is an effective alternative to topical formulations, particularly for patients with compliance issues.

Combined finasteride and topical minoxidil therapy yields better overall photographic assessment and more marked improvement compared with either monotherapy, while showing similar rates of moderate/mild improvement, hair density change, and adverse events.

Topical tretinoin for 5 days converted 43% of predicted minoxidil nonresponders to responders by upregulating follicular sulfotransferase.

Topical minoxidil and oral anti-androgens are the primary treatments aimed at halting progression and promoting cosmetically acceptable hair regrowth in female pattern hair loss.

Finasteride and minoxidil can halt disease progression but only yield partial hair regrowth; early initiation improves outcomes, and PRP may be considered for patients unresponsive to medical therapy.

Low-level laser therapy showed superior relative effects for hair regrowth compared to other non-surgical treatments, while PRP, finasteride, minoxidil, and dutasteride demonstrated approximately equivalent mean changes in hair count.

The combination of topical 0.25% finasteride and 3% minoxidil produced significantly greater improvements in hair density, hair diameter, and overall photographic assessment compared to minoxidil alone after 24 weeks, with about 90% of patients showing moderate to marked hair growth and minimal systemic effects.

Herbal drugs may reduce hair loss by inhibiting the 5-alpha-reductase enzyme with potentially fewer side effects than conventional pharmacological treatments.

The study investigated low-dose oral minoxidil for treating male pattern hair loss; specific efficacy results are not available from the abstract.

Dutasteride is found to be more effective than finasteride for treating androgenetic alopecia with comparable adverse effects.

First-line therapies recommended include oral finasteride 1 mg daily, oral dutasteride 0.5 mg daily, topical 5% minoxidil twice daily for MPHL and topical 1% minoxidil twice daily for FPHL, along with low-level laser therapy and hair transplantation.

The review highlights several emerging therapies, including novel excipients for oral minoxidil, dutasteride, and finasteride; topical prostaglandin modulators; low-level laser therapy; Wnt pathway activators and stem cell treatments for androgenetic alopecia; JAK inhibitors for alopecia areata; antiandrogens and pioglitazone for frontal fibrosing alopecia; and robotic-assisted follicular unit extraction for hair transplantation.

Minoxidil, finasteride, and low-level laser therapy were significantly more effective than placebo for promoting hair growth in men with androgenetic alopecia, and minoxidil was effective in women.

Topical minoxidil shows moderate efficacy in increasing hair regrowth and hair count in women with FPHL, with no clear advantage of 5% over 2% concentration; oral finasteride 1 mg is not more effective than placebo; low-level laser therapy may increase hair count but clinical relevance is uncertain.

Topical ketoconazole, minoxidil, and minoxidil plus tretinoin all promoted hair regrowth in male mice, with minoxidil alone showing the greatest effect.

Current treatments (minoxidil, finasteride) offer limited and non-permanent benefits; hair transplantation is the only permanent option, while other off-label agents and laser therapies are commonly used despite modest or inconsistent efficacy.

Treatments such as topical minoxidil and 5‑alpha reductase inhibitors (finasteride, dutasteride) can slow hair loss progression and promote regrowth, but continuous use is required to maintain benefit.

Minoxidil and finasteride remain the standard treatments, with hair transplantation as a surgical option; dutasteride, ketoconazole, and prostaglandin analogues (latanoprost, bimatoprost) are used or under investigation, and low-level laser therapy is gaining popularity, though robust clinical trial data proving hair growth efficacy are limited.

5% topical minoxidil produced significantly greater hair regrowth than 2% minoxidil and placebo, with 45% more regrowth versus 2% at week 48, earlier onset of response, and improved psychosocial perceptions of hair loss.

Both ketoconazole shampoo and minoxidil produced similar improvements in hair density, follicle size, and proportion of anagen follicles in patients with androgenic alopecia.